Reactions to HIV drug have autoimmune cause, reports AIDS journal

May 22, 2012 in HIV & AIDS

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according to a study published online by the journal AIDS, official journal of the International AIDS Society.

The study is the first to explain how hypersensitivity reactions to abacavir develop in genetically predisposed patients—and suggests that similar autoimmune mechanisms might account for other types of drug reactions related to variants in the human leukocyte antigen (HLA) system. The lead author is Dr Michael A. Norcross of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research. The publish-ahead-of-print article is currently available on the AIDS journal homepage and will be available in the July 17, 2012 print edition.

Abacavir Hypersensitivity Results from 'Drug-Induced Autoimmunity'

Dr Norcross and colleagues performed a series of laboratory experiments to examine why some patients develop hypersensitivity reactions to the antiretroviral drug abacavir (Ziagen—also included in combination products such as Epzicom and Trizivir). Developing a few weeks after the start of treatment, the reactions cause a wide range of symptoms including fever, rash, nausea, muscle soreness, and shortness of breath.

The reactions have been linked to a gene variant called HLA-B*57:01, found in up to eight percent of people of European descent (lower in other racial/ethnic groups). However, the molecular basis by which people with the HLA-B*57:01 gene develop hypersensitivity reactions to abacavir has been unclear.

In model cells expressing the HLA-B*57:01 gene product, the researchers found that abacavir induced a set of unique changes. Abacavir exposure led to the formation of new peptide molecules that bound to specific HLA-B*57:01 binding sites. The result was the creation of new drug-induced immunogens, which triggered attacks by immune cells.

These findings suggest that abacavir hypersensitivity reactions occur through an autoimmune mechanism—the attacks cells it doesn't recognize as "self." This is the same basic mechanism that causes autoimmune diseases such as lupus, inflammatory bowel disease, and type 1 diabetes.

This autoimmune mechanism helps to explain why abacavir hypersensitivity reactions can affect such a wide range of different organs and tissues. It also helps in understanding why the reactions clear up promptly when abacavir is stopped, and why more severe reactions can rapidly develop if treatment is restarted.

"Our data support a model of drug-induced autoimmunity as a consequence of abacavir exposure," Dr Norcross and colleagues write. They believe that a similar molecular mechanism could potentially explain other types of drug reactions involving HLA gene variants. It's also important to identify other factors influencing the development of hypersensitivity, since not all patients with the HLA-B*57:01 gene react to abacavir.

"This study provides important insight into why only certain people show this severe hypersensitivity to this valuable anti-HIV ," comments Dr J.A. Levy, Editor-in-Chief of . "The finding represents an example of how approaches to personalized medicine can identify patients who would be sensitive to this side effect of abacavir."

Provided by Wolters Kluwer Health

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Integrating mental health care into HIV care

The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...

HIV & AIDS created 11 hours ago | popularity not rated yet | comments 0

After a decade, global AIDS program looks ahead

(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...

HIV & AIDS created May 21, 2013 | popularity not rated yet | comments 0

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

HIV & AIDS created May 19, 2013 | popularity 5 / 5 (1) | comments 0

AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

HIV & AIDS created May 18, 2013 | popularity 5 / 5 (2) | comments 0

Peer-referral programs can increase HIV-testing in emergency departments

Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...

HIV & AIDS created May 17, 2013 | popularity not rated yet | comments 0


Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens

Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...